Cargando…
Evaluation of dose-efficacy of sorafenib and effect of transarterial chemoembolization in hepatocellular carcinoma patients: a retrospective study
BACKGROUND: Transarterial chemoembolization (TACE) and sorafenib are the therapeutic standard for intermediate and advanced stage hepatocellular carcinoma (HCC) patients respectively. High costs with adverse events (AE) of sorafenib might limit sorafenib dosage, further affecting therapeutic respons...
Autores principales: | Hsiao, Wang-De, Peng, Cheng-Yuan, Chuang, Po-Heng, Lai, Hsueh-Chou, Cheng, Ken-Sheng, Chou, Jen-Wei, Chen, Yang-Yuan, Yu, Cheng-Ju, Feng, Chun-Lung, Su, Wen-Pang, Chen, Sheng-Hung, Kao, Jung-Ta |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4847248/ https://www.ncbi.nlm.nih.gov/pubmed/27117280 http://dx.doi.org/10.1186/s12876-016-0464-x |
Ejemplares similares
-
Transarterial chemoembolization with or without sorafenib for hepatocellular carcinoma: A real-world propensity score-matched study
por: Peng, Tzu-Rong, et al.
Publicado: (2021) -
Beneficial Effect of Combining Radiotherapy and Transarterial Chemoembolization on Patient Survival in Hepatocellular Carcinomas and Macrovascular Invasion Treated with Sorafenib
por: Lu, Meng-Chuan, et al.
Publicado: (2023) -
Prognostic roles of diabetes mellitus and hypertension in advanced hepatocellular carcinoma treated with sorafenib
por: Hsieh, Ming-Han, et al.
Publicado: (2020) -
Transarterial Chemoembolization Combined with Sorafenib in Patients with BCLC Stage C Hepatocellular Carcinoma
por: Liu, Kai-Cai, et al.
Publicado: (2020) -
Transarterial chemoembolization combined with sorafenib for advanced hepatocellular carcinoma
por: SHAO, WENBO, et al.
Publicado: (2014)